BSGM — Biosig Technologies Share Price
- $36.99m
- $36.96m
- $0.04m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 924.84 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | -25877.5% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | 0.44 | 0.29 | 0.02 | 0.04 | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
BioSig Technologies, Inc. is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. The Company’s product, the PURE EP Platform, a non-invasive class II device, provides real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures. Integrating with existing systems in the EP lab, PURE EP is designed to pinpoint even the complex signals to maximize procedural success and efficiency. The PURE EP System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time.
Directors
- Kenneth Londoner CHM (53)
- Steven Chaussy CFO (67)
- Gray Fleming OTH
- James Barry IND
- Donald Foley IND (69)
- Patrick Gallagher IND (56)
- Samuel Navarro IND (65)
- David Weild IND (64)
- Anthony Zook IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 21st, 2011
- Public Since
- September 22nd, 2014
- No. of Shareholders
- 421
- No. of Employees
- 5
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market
- Shares in Issue
- 27,002,482

- Address
- 55 Greens Farms Road, WESTPORT, 06880
- Web
- https://www.biosig.com/
- Phone
- +1 2034095444
- Auditors
- Marcum LLP
Upcoming Events for BSGM
Q2 2025 BioSig Technologies Inc Earnings Release
Similar to BSGM
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
As of Today at 19:36 UTC, shares in Biosig Technologies are trading at $1.37. This share price information is delayed by 15 minutes.
Shares in Biosig Technologies last closed at $1.37 and the price had moved by -23.03% over the past 365 days. In terms of relative price strength the Biosig Technologies share price has underperformed the S&P500 Index by -30.6% over the past year.
The overall consensus recommendation for Biosig Technologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBiosig Technologies does not currently pay a dividend.
Biosig Technologies does not currently pay a dividend.
Biosig Technologies does not currently pay a dividend.
To buy shares in Biosig Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.37, shares in Biosig Technologies had a market capitalisation of $36.99m.
Here are the trading details for Biosig Technologies:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BSGM
Based on an overall assessment of its quality, value and momentum Biosig Technologies is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biosig Technologies is $2.50. That is 82.48% above the last closing price of $1.37.
Analysts covering Biosig Technologies currently have a consensus Earnings Per Share (EPS) forecast of -$0.20 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biosig Technologies. Over the past six months, its share price has outperformed the S&P500 Index by +23.99%.
As of the last closing price of $1.37, shares in Biosig Technologies were trading +57.83% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biosig Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biosig Technologies' management team is headed by:
- Kenneth Londoner - CHM
- Steven Chaussy - CFO
- Gray Fleming - OTH
- James Barry - IND
- Donald Foley - IND
- Patrick Gallagher - IND
- Samuel Navarro - IND
- David Weild - IND
- Anthony Zook - IND